Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 1.25 HKD -3.1% Market Closed
Market Cap: 989.7m HKD
Have any thoughts about
Jacobio Pharmaceuticals Group Co Ltd?
Write Note

Jacobio Pharmaceuticals Group Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jacobio Pharmaceuticals Group Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Cost of Revenue
-ÂĄ60.3m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cost of Revenue
-ÂĄ1.3B
CAGR 3-Years
-46%
CAGR 5-Years
-100%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ27.3B
CAGR 3-Years
-29%
CAGR 5-Years
-38%
CAGR 10-Years
-57%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-ÂĄ140.8m
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Jacobio Pharmaceuticals Group Co Ltd
Glance View

Market Cap
989.7m HKD
Industry
Biotechnology

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Intrinsic Value
0.85 HKD
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Jacobio Pharmaceuticals Group Co Ltd's Cost of Revenue?
Cost of Revenue
-60.3m CNY

Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Cost of Revenue amounts to -60.3m CNY.

What is Jacobio Pharmaceuticals Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-11%

Over the last year, the Cost of Revenue growth was 27%. The average annual Cost of Revenue growth rates for Jacobio Pharmaceuticals Group Co Ltd have been -11% over the past three years .

Back to Top